Trump Tariffs on Drugs: A Blow to Pharma

Trump Administration Imposes Tariffs on Imported Drugs, Aiming to Boost US Production

The Trump administration has implemented tariffs of up to 100% on certain imported patented drugs, targeting countries without trade deals and companies lacking special pricing pacts. Exemptions soften the blow for many, including the European Union, South Korea, Japan, Switzerland, and Liechtenstein, which cap out at 15%. The UK gets an even lower rate after pledging to boost medicine spending. Companies committing to some US manufacturing pay 20%, and those with full pricing deals pay zero through January 2029. Big names like Merck and Eli Lilly sidestepped the worst by cutting deals last summer, leaving smaller pharmas and ingredient suppliers to bear most of the pain. Biotech leaders warn these tariffs will spike costs, mess with supply chains, and slow new treatments, especially for cash-strapped startups. Generics dodge them now, but the Commerce Department reviews that in one year based on reshoring progress. Specialty drugs for rare diseases or animal health often get passes too. This move stems from a national security probe under Section two thirty-two, part of Trumps protectionist playbook despite court losses on broader tariffs. Drug firms now choose: absorb hits or pass them on, potentially hiking copays and premiums in the worlds priciest drug market.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
[email protected]

This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].

View sources & latest updates:
https://sources.thednn.ai/304d7b65d14b31f4